7、524acc/ada共同指出:血脂控制力度还需加大危险程度危险程度目标值目标值ldl-cnon-hdl-c(mg/dl)apob(mg/dl)极高危患者极高危患者包括:包括:1)已知已知cvd;2)糖尿病,合并至糖尿病,合并至少一个其它主要少一个其它主要cvd危险因素危险因素70mg/dl(1.8mmol/l)10080高危患者高危患者包括:包括:1)无糖尿病或已...
Only 31% of patients achieved LDL-c goals of ≤70 mg/dL, without gender differences, a percentage which further dropped to 15% after establishing the target below 55 mg/dL. Patients with concurrent atrial fi brillation (34.9% vs. 25.1%, p=0.006), heart failure (37.1% vs. 27.2%, p=...
In the ODYSSEY ALTERNATIVE trial, alirocumab produced greater LDL-C reduction compared with ezetimibe in patients intolerant to statins (45% and 14.6% at week 24, respectively), and a higher percentage of patients reached the recommended LDL-C goal (41.9% vs 4.4%, respectively) (Moriarty et ...
HbA1c goal (<7.0% in 60.6%) was attained more frequently than LDL-C goal (<70 mg/dl in 39.9%; p < .01). Significantly more participants named the correct goal for HbA1c compared to LDL-C (52.9% vs. ...
More than 70% of patients who stopped due to side effects tolerated the statin when it was restarted36. Although we have no information on adherence, we hypothesise that not all patients took the prescribed medication correctly. Adherence issues especially apply to the “increasing” and “high-...
et al. Gender disparities in lipid goal attainment among type 2 diabetes outpatients with coronary heart disease: Results from the CCMR-3B Study. Sci. Rep. 7, 12648 (2017). 42. Rossi, M. C. et al. Sex disparities in the quality of diabetes care: Biological and cultural factors may ...
Demographic, HgbA1c, and LDL-C data were obtained and an analysis was conducted for goal attainment of HgA1c and LDL-C according to race and gender, between African American (AA) patients and Caucasian (C) patients. Results: The cohort contained 7,458 patients, [Male (M)=3,768, Female...
Therefore, our results suggest that the effects of rs3733197 and statins on systemic lupus erythematosus may be related, and an improved understanding of the role of LDL cholesterol in these contexts should be a goal of future studies. In conclusion, we identified a novel functional variant of ...
Effect of alirocumab dose increase on LDL lowering and lipid goal attainment in patients with dyslipidemia Coron Artery Dis, 28 (2017), pp. 190-197 View in ScopusGoogle Scholar 12 E.M. Roth, P.M. Moriarty, J. Bergeron, et al. A phase III randomized trial evaluating alirocumab 300 mg ev...
Genetic variation of NPC1L1, the molecular target of ezetimibe, is associated with variability in cholesterol absorption [55] and differential responsiveness to ezetimibe treatment [56], and may also play a role. As expected, statin potency was significantly associated with LDL-C lowering for the ...